As more of us choose a different way to die, a philosophy has become an industry, raising questions about access, quality—and profits.
Disgraced stem-cell scientist Woo Suk Hwang has become exhibit A in the case for tightening scrutiny of apparent medical advances.
Transplant surgeon Amy Friedman argues: Since we can’t get enough organs for free, why not pay for them?
As today’s caregivers face a rainbow of cultures, issues of race, religion and language can make or break a treatment plan.
The testing of artificial blood has sparked controversy over individual rights.
Television portrays ERs as high-tech places where everyone gets saved. But what’s the real deal?
Pay for performance seems simple: Give doctors financial incentives to improve care. So what’s taking so long?
No-name drugs may be cheaper than brand names, but they have some drawbacks as well.
Debora Spar of the Harvard Business School argues that new medical technology can’t go unregulated forever.
The National Institutes of Health fund much of U.S. medical research. Could budget cuts stem the flow of breakthroughs?
No Articles Found.